Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dominion Energy Inc (D) vs Gilead Sciences, Inc. (GILD) Price & Performance

Dominion Energy IncTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Dominion Energy Inc vs Gilead Sciences, Inc. — how do they compare? Dominion Energy Inc trades at $67.56 (market cap $59.06B), while Gilead Sciences, Inc. trades at $135.99 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× Dominion Energy Inc's market cap, and Dominion Energy Inc pays the higher dividend (3.98%). Which is the better fit depends on your goals.

DGILD
Market Cap
$59.06B$164.99B
Sector
UtilitiesHealth
52-Week High
$71.67$155.80
52-Week Low
$57.08$110.56
Enterprise Value
$113.18B$188.06B
Dividend Yield
3.98%2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dominion Energy Inc

Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.

Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dominion Energy Inc

Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.

Read more on D

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD